✦ LIBER ✦

Phase I/II trial of intravesical methotrexate for superficial bladder tumors

✍ Scribed by Cora N. Sternberg; Alan Yagoda; Neil H. Bander; Willet F. Whitmore; Jeffry L. Huffman; Martin Fleisher; Myron Melamed; Michael P. Fanucchi; Phyllis Hollander; E. Darracott Vaughan

Book ID: 104696911
Publisher: Springer
Year: 1986
Tongue: English
Weight: 484 KB
Volume: 18
Category: Article
ISSN: 0344-5704
DOI: 10.1007/bf00273400

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Phase I trial of intravesical Suramin in

Phase I trial of intravesical Suramin in recurrent superficial transitional cell bladder carcinoma

✍ Ord, J J; Streeter, E; Jones, A; Le Monnier, K; Cranston, D; Crew, J; Joel, S P; 📂 Article 📅 2005 🏛 Nature Publishing Group 🌐 English ⚖ 223 KB

Intravesical doxorubicin for the prophyl

Intravesical doxorubicin for the prophylaxis of superficial bladder tumors. A multicenter study

✍ Dr. Claudio Intini; BLINST ITALIAN COOPERATIVE GROUP 📂 Article 📅 1984 🏛 John Wiley and Sons 🌐 English ⚖ 490 KB 👁 2 views

IS THERE A ROLE FOR RECOMBINANT TUMOR NE

IS THERE A ROLE FOR RECOMBINANT TUMOR NECROSIS FACTOR ALPHA IN THE INTRAVESICAL TREATMENT OF SUPERFICIAL BLADDER TUMORS?—A PHASE II STUDY

✍ V Serretta; B Piazza; C Pavone; S Piazza; M Pavone-Macaluso 📂 Article 📅 1995 🏛 John Wiley and Sons 🌐 English ⚖ 331 KB

Intravesical chemotherapy of superficial

Intravesical chemotherapy of superficial bladder tumors in a controlled trial with cis-platinum versus Cis-platinum plus hyaluronidase

✍ Yoav Horn; Avraham Eidelman; Natalio Walach; Mordechai Waron; Frida Barak 📂 Article 📅 1985 🏛 John Wiley and Sons 🌐 English ⚖ 337 KB

Intravesical administration of gemcitabi

Intravesical administration of gemcitabine in superficial bladder cancer: a phase I study with pharmacodynamic evaluation

✍ E. De Berardinis; G. Antonini; G.J. Peters; W.J.P. Loves; K. Van Der Born; G. Co 📂 Article 📅 2004 🏛 John Wiley and Sons 🌐 English ⚖ 73 KB

A Phase II trial of gemcitabine for meta

A Phase II trial of gemcitabine for metastatic neuroendocrine tumors

✍ Matthew H. Kulke; Haesook Kim; Jeffrey W. Clark; Peter C. Enzinger; Thomas J. Ly 📂 Article 📅 2004 🏛 John Wiley and Sons 🌐 English ⚖ 77 KB

## Abstract ## BACKGROUND Treatment with traditional cytotoxic chemotherapy regimens containing streptozocin or dacarbazine has resulted in only marginal benefit for patients with metastatic neuroendocrine tumors. The use of these regimens has been further limited by their potential toxicity. Gemc